Quinta-Analytica

Quinta-Analytica is a specialized service provider for the pharmaceutical industry, offering comprehensive pharmaceutical analysis, research and development, and clinical testing to ensure compliance with strict regulatory standards. Quinta-Analytica, founded in 1997, operates primarily in the Czech Republic and engages in pharmaceutical analysis and clinical testing. The company has undergone no significant pivots in its business strategy and does not have known subsidiaries or parent companies. The CEO, Roman Grunt, has been instrumental in guiding the firm since its inception.

Quinta-Analytica has been involved in 2 total deals, with the most recent deal occurring on November 30, 2021. Quinta-Analytica specializes in providing a comprehensive range of services to the global pharmaceutical industry, focusing on pharmaceutical analysis, research and development (R&D), and clinical testing for both human and veterinary medicinal products. Their core offerings include validation of analytical methods, quality control, stability studies, and batch release, which ensure that pharmaceutical products meet stringent regulatory standards. Additionally, Quinta's in-house Clinical Units have successfully conducted over 300 bioequivalence, pharmacokinetics, and bridging studies since 2007, demonstrating their capability in clinical testing.

The company serves a diverse client base, including pharmaceutical manufacturers, biotechnology firms, and regulatory agencies across Europe, the United States, and Asia. Their extensive expertise across various analytical services positions them as a trusted partner in developing and ensuring compliance for innovative medicinal products. In 2022, Quinta-Analytica reported a revenue of USD 16. 56 mn and an EBITDA of USD 2.

91 mn. Revenue is generated through a structured approach to transactions with clients in the pharmaceutical sector, primarily through B2B partnerships. Clients procure services on a project basis, encompassing analytical testing, clinical study management, and related regulatory compliance tasks. The company’s flagship services, such as bioanalytical method validation and pharmacovigilance, are integral to their clients' development processes, ensuring that medicines are safe and effective for public use.

The pricing structure is typically tailored to the specific needs of each project, reflecting the complexity and scope of services rendered. Such transactional dynamics foster long-term relationships with clients, who rely on Quinta-Analytica’s expertise to navigate regulatory landscapes and achieve successful product development outcomes. Following the acquisition of a majority stake by LVA GmbH in November 2021, Quinta-Analytica aims to leverage new resources to expand its product offerings and geographic reach. The company is working on developing new analytical testing services to meet the evolving needs of the pharmaceutical industry, with plans for a rollout by late 2023.

They also intend to expand their operations into new markets, particularly targeting North America and Asia by 2024. The recent funding from the acquisition will be utilized to support these initiatives, enhancing the company’s capabilities in research and development.